Skip to main content
Frontier Biotechnologies Inc. logo

Frontier Biotechnologies Inc. — Investor Relations & Filings

Ticker · 688221 ISIN · CNE100005XF5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2021-02-01 Remuneration Information
Country CN China
Listing Shanghai Stock Exchange 688221

About Frontier Biotechnologies Inc.

https://www.frontierbiotech.com/

Frontier Biotechnologies Inc. is a biopharmaceutical company focused on the research, development, and commercialization of innovative medicines, particularly in the field of anti-infectives. The company's flagship product is albuvirtide, a long-acting HIV fusion inhibitor administered via injection. This therapeutic represents a significant advancement in HIV management by providing a long-acting alternative to daily oral regimens. Frontier Biotechnologies maintains a diverse pipeline of clinical-stage candidates, including protease inhibitors developed for the treatment of COVID-19. The company leverages its proprietary technology platforms to develop long-acting peptide drugs and small molecule therapeutics targeting unmet medical needs in infectious diseases and chronic conditions. Its core operations encompass the full drug development lifecycle, from discovery and clinical trials to manufacturing and commercial distribution.

Recent filings

Filing Released Lang Actions
前沿生物2021年限制性股票激励计划首次授予激励对象名单
Remuneration Information Classification · 95% confidence The document is titled as a list of recipients for a 2021 restricted stock incentive plan by the company. It details the allocation of restricted stock to directors, senior management, and other employees. There is no indication of financial statements, audit information, or regulatory certifications. The document is a disclosure related to share-based compensation, specifically the initial grant of restricted stock under an incentive plan. This type of document is best classified under Remuneration Information (DEF 14A), which covers reports detailing compensation for top executives and directors, including stock incentive plans.
2021-02-01 Chinese
国浩律师（南京）事务所关于前沿生物药业（南京）股份有限公司2021年限制性股票激励计划的法律意见书
Remuneration Information Classification · 95% confidence The document is a detailed legal opinion letter from a law firm regarding a 2021 restricted stock incentive plan for a listed company, 前沿生物药业(南京)股份有限公司. It discusses the legal compliance, procedures, qualifications of incentive recipients, and the impact on shareholders. It references relevant laws, regulatory approvals, board and supervisory committee meetings, and independent opinions. The document is not a financial report, earnings release, or a simple announcement. It is a legal opinion specifically related to a stock incentive plan, which is a form of remuneration information concerning executive and director compensation and incentives. Therefore, the document fits best under the category of Remuneration Information (DEF 14A).
2021-02-01 Chinese
前沿生物关于第二届董事会第十七次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at the 17th meeting of the second board of directors of the company. It details board meeting procedures, voting results, and proposals related to stock incentive plans, guarantees for subsidiaries, amendments to the company charter, and the scheduling of a shareholders meeting. It does not contain financial statements or detailed financial performance data. The content focuses on board decisions and governance matters. Therefore, it fits the category of Board/Management Information (MANG). The document length is 4112 characters, which is consistent with a detailed announcement but not a full report. Hence, the classification is MANG with high confidence.
2021-02-01 Chinese
前沿生物关于修订《公司章程》的公告
Governance Information Classification · 95% confidence The document is an announcement regarding the revision of the company's Articles of Association (公司章程). It details specific amendments to the company's governance documents and states that the changes will be submitted to the shareholders' meeting for approval. There is no financial data, no mention of annual or interim reports, earnings, or other financial disclosures. The focus is on governance structure and internal rules. This fits the definition of Governance Information (CGR). The document length is short and it is not merely announcing the publication of a report but providing substantive content about governance changes.
2021-02-01 Chinese
前沿生物2021年限制性股票激励计划（草案）摘要公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement of a 2021 restricted stock incentive plan (股权激励计划) by a company named 前沿生物药业（南京）股份有限公司. It includes specifics about the stock incentive plan such as the number of shares, pricing, eligibility, vesting conditions, performance targets, and legal compliance. The content focuses on the company's internal stock incentive scheme for directors, senior management, and key employees, which is a form of equity compensation. This type of document is typically classified as a Capital/Financing Update (CAP) because it relates to changes in the company's capital structure through issuance of shares to employees as part of an incentive plan. It is not an Annual Report, Earnings Release, or Management Report, nor is it a regulatory filing or announcement of voting results. The document is substantive and detailed, not a brief announcement or certification. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2021-02-01 Chinese
前沿生物关于独立董事公开征集委托投票权的公告
Proxy Solicitation & Information Statement Classification · 95% confidence The document is an announcement by a company's independent director soliciting proxy voting rights from shareholders for an upcoming extraordinary general meeting (EGM) scheduled on February 25, 2021. It details the proxy solicitation process, voting instructions, and the agenda items related to a stock incentive plan. The document does not contain financial statements or results but is focused on the solicitation of votes and proxy authorization. This fits the definition of Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings. The document length is 4560 characters, which is consistent with a detailed proxy solicitation notice rather than a full report or announcement of a report publication. Therefore, the correct classification is PSI.
2021-02-01 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.